Benzinga | Jul 26, 2021 09:02AM EDT

NeuroMetrix Announces Peer-Reviewed Publication Of Randomized Controlled Trial Of Its Wearable Neurostimulation Technology For Treatment Of Fibromyalgia

NeuroMetrix, Inc. (NASDAQ:NURO) today announced a publication titled "Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website.



The article reports an intention-to-treat analysis of a double-blind, randomized, sham-controlled trial that compared 3-months of at-home treatment with a standard (active) or low dose (sham) Quell device in 119 subjects with fibromyalgia.

Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA).